Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.


TSX:OPS - Post by User

Comment by Possibleidiot01on Apr 13, 2023 7:50am
109 Views
Post# 35392421

RE:RE:RBC Report

RE:RE:RBC Report
bossu wrote: I would rather worry about the cash burning rate per quarter.
Cash equivalent 
-$23.8-million at Aug. 31, 2022
-Cash and cash equivalents of $17.5-million at Nov. 30, 2022
-Burning rate /quarter $ 6,3 M   (Q1 2023)
  • In December, 2022, the company closed an $11.5-million bought deal offering.
  • Cash and cas equivalent  to be  $ 29 M after the financing 
  • Assuming a cash and cash equivalent at say $ 20 M would mean a cash burning rate of  $ 9.0 for the quarter .... a number that I care about
  • top line revenue has to increase from Q1 2023/Q2 
  • and bottom line less than $ 3 ,6 M loss
 
Number to watch    Top line.........has to be higher
...............................Bottom line..... lower loss
..............................Burning rate ....about the same as the Q1 2023 and not more than the Q1 2923

Just to say we need ''good news''

If it's not the case OPS to ''suffer''






Going to use your numbers. so $29 million.
Cash at February 28 - $21.9 million.
$7.1 million cash burn.
$2.9 million used for sales and marketing .

Structural heart sales, despite being in controlled release in the U.S. market, were $0.5 million in the second quarter of 2023, driven by a 31% sequential increase in sales as compared to the first quarter of 2023.
That's SavvyWire sales startup sales with limited U.S. availability.

<< Previous
Bullboard Posts
Next >>